1.Kikuchi H, Sakakibara-Konishi J, Furuta M, Yokouchi H, Nishihara H, Yamazaki S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Harada T, Higuchi M, Honjo O, Minami Y, Watanabe N, Oizumi S, Suzuki H, Ishida T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M. Expression of Notch1 and Numb in small cell lung cancer. Oncotarget. 8(6):10348-10358, 2017.
2.Pham TD, Watanabe Y, Higuchi M, Suzuki H. Texture Analysis and Synthesis of Malignant and Benign Mediastinal Lymph Nodes in Patients with Lung Cancer on Computed Tomography. Sci Rep. 7:43209, 2017.
3.Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M. Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker. Oncotarget. 8(24): 39711-39726, 2017
4.Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today. [Epub ahead of print]
5.Higuchi M, Takagi H, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Osugi J, Hoshino M, Shio Y, Fujiu K, Kanno R, Ohishi A, Suzuki H, Gotoh M. Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons. Oncol Lett 13 :4315-4321, 2017
6.Muto S, Takagi H, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Suzuki H. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients. Anticancer Res 37 (6) 3169-3174, 2017
7.Fukuhara M, Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Muto S, Hasegawa T, Suzuki H. Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. Journal of Thoracic Disease 9(6):1592-1597, 2017.
8.Matsumura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Hasegawa T, Hoshino M, Osugi J, Higuchi M, Suzuki H. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinomaInteractive. Interactive CardioVascular and Thoracic Surgery. ivx207, 2017.
9.Mai T, Takano A, Suzuki H, Hirose T, Mori T, Teramoto K, Kiyotani K, Nakamura Y, Daigo Y. Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. Oncol Lett. 14(1): 283-292, 2017.
10.Matsumura Y, Suzuki H, Ohira T, Shiono S, Abe J, Sagawa M, Sakurada A, Katahira M, Machida Y, Takahashi S, Okada Y. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer. 114; 23-30, 2017.
11.Okabe N, Takagi H, Mine H, Fukai S, Minemura H, Suzuki H. Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma. Journal of Thoracic Oncology 12(10): e155-e173, 2017.
12.Inoue T, Takagi H, Owada Y, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Osugi J, Hoshino M, Higuchi M, Shio Y, Yokouchi H, Kanazawa K, Ohbuchi K, Fukushima T, Munakata M, Suzuki H. Efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial. Trials. 18:485, 2017
13.Yamaura T, Ezaki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Muto S, Matsumura Y, Hasegawa T, Hoshino M, Osugi J, Shio Y, Waguri S, Tamura H, Imai J, Ito E, Yanagisawa Y, Honma R, Watanabe S, Suzuki H. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. Oncology Letters. In press
欧文総説
1.Higuchi M, Nemoto T, Matsuida H, Oshibe I, Soeta N, Takeshige T, Saito T, Suzuki H. Current status and future prospects of PET/CT in NSCLC treated with checkpoint-based immunotherapy. J Rare Dis Res Treat. 2(2): 43-49, 2017
